Oncology (all articles)
Randomized trial: Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) improve outcomes vs. traditional approach in locally advanced rectal cancer
12 Jan, 2021 | 01:12h | UTCShort-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
New online: phase 3 RAPIDO trial: Short-course #radiotherapy followed by #chemotherapy before total mesorectal excision (TME) vs standard of care in locally advanced #rectalcancer https://t.co/bTgUC6Lo39 #crcsm pic.twitter.com/Iu3HbQ1xjG
— The Lancet Oncology (@TheLancetOncol) December 8, 2020
Meta-analysis: Total neoadjuvant therapy vs. standard therapy in locally advanced rectal cancer
12 Jan, 2021 | 01:10h | UTCCommentaries: Personalizing Treatment for Rectal Cancer: Total Neoadjuvant Therapy Is Leading the Way AND Total Neoadjuvant Therapy Improves Rectal Cancer Pathologic Response – Physician’s Weekly
Related meta-analysis (just published): Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials – Cancers
Commentary on Twitter
Systematic review & meta-analysis finds total neoadjuvant therapy for locally adv. rectal cancer is associated with a doubling of pathologic complete response vs standard chemoradiation plus by adjuvant chemo. @anup_kasi @KUMedCenter @geriradonc @agrothey https://t.co/oRccCh5bEb
— JAMA Network Open (@JAMANetworkOpen) December 16, 2020
Study suggests the intensity of active surveillance in patients with rectal cancer managed by a watch-and-wait approach could be reduced if they maintain a complete clinical response within the first 3 years
12 Jan, 2021 | 01:11h | UTCCommentaries: Rectal cancer patients who “watch and wait” may only need few years of stringent follow-up – eCancer AND Intense rectal cancer surveillance may be reduced – MDedge
Meta-analysis: Lung cancer screening using low-dose computed tomography reduces lung cancer–specific mortality, albeit with a tradeoff of likely overdiagnosis
16 Dec, 2020 | 10:08h | UTC
Randomized trial: Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer does not benefit patients vs. surgery alone
16 Dec, 2020 | 09:55h | UTCExtensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary on Twitter
ICYMI – Results of the EXPEL trial show no survival benefit with extensive peritoneal #lavage after surgery vs surgery alone; not recommended for patients undergoing curative #gastrectomy for #gastriccancer.https://t.co/rCgHNt7VZ1#gitwitter #some4surgery pic.twitter.com/BC1BJgElYm
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 9, 2020
Brazilian Cardio-oncology Guideline – 2020
15 Dec, 2020 | 01:31h | UTCBrazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia
Randomized trial: Among patients with advanced rectal cancer, short-course radiotherapy followed by chemotherapy before total mesorectal excision reduces disease-related treatment failure compared to standard treatment
15 Dec, 2020 | 01:29h | UTC
Commentary on Twitter
New online: phase 3 RAPIDO trial: Short-course #radiotherapy followed by #chemotherapy before total mesorectal excision (TME) vs standard of care in locally advanced #rectalcancer https://t.co/bTgUC6Lo39 #crcsm pic.twitter.com/Iu3HbQ1xjG
— The Lancet Oncology (@TheLancetOncol) December 8, 2020
A nationwide study in Denmark showed a higher than expected risk of cardiac events in patients with cancer receiving immune checkpoint inhibitors
10 Dec, 2020 | 08:49h | UTC
Short review: How to diagnose and manage radiation therapy cardiotoxicity
6 Dec, 2020 | 23:27h | UTCHow to Diagnose and Manage Radiation Cardiotoxicity – JACC: CardioOncology
Case series: Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer
2 Dec, 2020 | 07:31h | UTC
Randomized trial: Colorectal cancer screening with repeated fecal immunochemical tests detects more colorectal cancer and advanced adenomas compared to screening sigmoidoscopy
25 Nov, 2020 | 09:05h | UTCColorectal cancer screening with repeated fecal immunochemical test versus sigmoidoscopy: baseline results from a randomized trial – Gastroenterology (link to abstract – $ for full-text)
Systematic review: Interventions for breathlessness in patients with advanced cancer
23 Nov, 2020 | 09:43h | UTCFull report: Interventions for breathlessness in patients with advanced cancer
Evidence Summary: Interventions for breathlessness in patients with advanced cancer
Treatment of community-acquired pneumonia in immunocompromised adults: A consensus statement regarding initial strategies
17 Nov, 2020 | 09:40h | UTCEditorial: Management of Community-Acquired Pneumonia in Immunocompromised Adults – CHEST
Guideline synopsis for follow-up colonoscopy after polypectomy. Repeat Col in 7 to 10 y after 1 to 2 tubular adenomas (TA) < 10 mm; Repeat Col in 3 to 5 y after 3 to 4 TA < 10 mm; Repeat Col in 3 y after 5 to 10 TA < 10 mm; Repeat Col in 3 years after 1 or more TA > 10 mm
9 Nov, 2020 | 01:17h | UTCRecommendations for Follow-up Colonoscopy After Polypectomy – JAMA (free for a limited period)
Author interview: New Recommendations for How Often to Repeat Colonoscopy Following Polypectomy
Original guideline: Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer – Gastroenterology
Meta-analysis: Increased mortality due to cancer treatment delay
5 Nov, 2020 | 09:03h | UTCMortality due to cancer treatment delay: systematic review and meta-analysis – The BMJ
Editorial: Prioritising research into cancer treatment delays – The BMJ
Commentary on Twitter
People whose treatment for cancer is delayed by even one month have in many cases a 6 to 13% higher risk of dying – a risk that keeps rising the longer their treatment does not begin, suggests new research @HannaRadOnc https://t.co/KAmY3vx9jy
— The BMJ (@bmj_latest) November 5, 2020
[Abstract Only] Randomized, open-label trial: Olanzapine seems effective for the prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy
5 Nov, 2020 | 08:48h | UTCOlanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
RCT of adding Olanzapine to Nausea regimen (aprepitant, ondan, dex)
231 children, cycle 1 of highly emetogenic chemo
Primary endpoint: complete response= no vomiting + no rescue med use
78% v 59% day 1
74% v 47% days 1-5
64% v 38% overall#supponc https://t.co/cZFM8bLXKg— Arjun Gupta (@guptaarjun90) September 16, 2020
Study provides new estimates of breast cancer risks associated with different hormone replacement therapy preparations
30 Oct, 2020 | 01:04h | UTCCommentaries: Study provides new estimates of breast cancer risks associated with HRT – University of Oxford AND New estimates of breast cancer risks associated with HRT – The BMJ AND HRT: Breast Ca Risk Tied to Hormone Type, Duration of Tx – Physician’s Weekly
KDIGO Controversies Conference on onco-nephrology
30 Oct, 2020 | 01:03h | UTC
Commentary on Twitter
.@goKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer ca. 2020 from @Kidney_Int #Nephpearls#Onconephrology 🦀
👉🏼 https://t.co/u6ANtXdKfy pic.twitter.com/4xJ0gGohoE— Edgar V. Lerma 🇵🇭 (@edgarvlermamd) October 28, 2020
Randomized trial: Osimertinib in resected EGFR-Mutated non–small-cell lung cancer
29 Oct, 2020 | 09:04h | UTCOsimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer – New England Journal of Medicine
A systematic review of rehabilitation and exercise recommendations in oncology guidelines
29 Oct, 2020 | 09:02h | UTC
Commentary on Twitter
Improving the integration of rehabilitation into cancer care: A review of #oncology guidelines and their recommendations for #rehabilitation and #exercise https://t.co/QRerXhhGON #cancerehab #exerciseoncology @NicoleStoutPT @JulieSilverMD @KarenPhysio @DR_SantaMina @WVUCancer pic.twitter.com/kObsSMRN9A
— CA: A Cancer Journal for Clinicians (@CACancerJournal) October 27, 2020
USPSTF draft statement now recommends starting colorectal cancer screening at 45
28 Oct, 2020 | 08:57h | UTCDraft Recommendation Statement: Colorectal Cancer Screening – U.S. Preventive Services Task Force
Commentaries: Colorectal cancer screening should start five years earlier — at 45 — expert panel says – STAT AND USPSTF Lowers Colorectal Cancer Screening Age to 45 in Draft Recommendation – NEJM Journal Watch
Clinical review: New advances in the diagnosis and management of hepatocellular carcinoma
28 Oct, 2020 | 08:47h | UTCNew advances in the diagnosis and management of hepatocellular carcinoma – The BMJ (free for a limited period)
Commentary on Twitter
https://twitter.com/bmj_latest/status/1320817899599241216
Radiation therapy for rectal cancer: Executive summary of an ASTRO clinical practice guideline
28 Oct, 2020 | 08:45h | UTCCommentaries: ASTRO issues clinical guideline on radiation therapy for rectal cancer AND ASTRO Issues Guideline on Radiation Therapy for Rectal Cancer – Physician’s Weekly
Commentary on Twitter
ASTRO issues clinical guideline on #RadiationTherapy for #RectalCancer. Recommendations address #patient selection and treatment techniques for locally advanced disease. This new guideline is published in the #PracticalRO Journal: https://t.co/Q6BDPAOxRI #RadOnc pic.twitter.com/9Zzj5BWA2o
— ASTRO (@ASTRO_org) October 21, 2020
ASCO Guideline Update: Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer
27 Oct, 2020 | 09:32h | UTC
Meta-analysis: Evaluating prophylactic heparin in ambulatory patients with solid tumors
22 Oct, 2020 | 09:23h | UTCEvaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis – The Lancet Haematology (free registration required)